Quick Answer
Sulforaphane Blood Glucose Randomized Trial has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: The positive symptoms manifest as hallucinations, delusions, and disorganized speech or behavior, while the negative symptoms consist of cognitive impairment with reduced motivation and expressiveness factors that affect memory and mental processing [,].
Key Takeaways
- 01The positive symptoms manifest as hallucinations, delusions, and disorganized speech or behavior, while the negative symptoms consist of cognitive impairment with reduced motivation and expressiveness factors that affect memory and mental processing [,]. [Kassar Omar (2025)]
- 02Patients with schizophrenia have a mortality rate of 2-3-fold compared to healthy people, with a reduced expected life of 10–20 years []. [Kassar Omar (2025)]
- 03The main goal of antipsychotics is restoring the patient’s normal daily functioning, followed by maintenance doses of therapy to prevent the risk of hospitalization and improve quality of life []. [Kassar Omar (2025)]
- 041 2 3 4 5 6 7 Schizophrenia is one of the most prevalent long-term disabling psychiatric disorders, affecting around 0.7% to 1% of the general population []. [Kassar Omar (2025)]
The current Migaku evidence database contains 2 reusable source documents for Sulforaphane Blood Glucose Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts.
- The positive symptoms manifest as hallucinations, delusions, and disorganized speech or behavior, while the negative symptoms consist of cognitive impairment with reduced motivation and expressiveness factors that affect memory and mental processing [,]. [Kassar Omar (2025); evidence level 1]
- Patients with schizophrenia have a mortality rate of 2-3-fold compared to healthy people, with a reduced expected life of 10–20 years []. [Kassar Omar (2025); evidence level 1]
- The main goal of antipsychotics is restoring the patient’s normal daily functioning, followed by maintenance doses of therapy to prevent the risk of hospitalization and improve quality of life []. [Kassar Omar (2025); evidence level 1]
- 1 2 3 4 5 6 7 Schizophrenia is one of the most prevalent long-term disabling psychiatric disorders, affecting around 0.7% to 1% of the general population []. [Kassar Omar (2025); evidence level 1]
- Substantial evidence has supported the beneficial role of healthy dietary factors in preventing the occurrence and development of CMDs and atherosclerosis in the aging population [,,,]. [Wu Qi (2026); evidence level 2]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources
- Efficacy and safety of sulforaphane in schizophrenia: a systematic review and meta-analysis of randomized controlled trials
- Effects of a cardiometabolic risk–reducing dietary pattern health education intervention on cardiometabolic disease risk in community-dwelling older adults in China: a cluster-randomized clinical trial